Komori
Revision to earnings forecast4547KISSEI PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)

The full-year forecast for the fiscal year ending March 2027 was revised, with upward revisions to net sales, operating profit and ordinary profit, while net income attributable to owners of the parent was revised downward due to the impact of extraordinary losses. Interim results were also disclosed at the same time.

Worth reading
75Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-3300
¥ million
Wording
Conditional
How definitive the wording is.

Revised forecast

Fiscal year ending March 2027 · Full yearPrevious forecast published July 2026
Net Sales88,700→89,000million
+0.3%
Operating profit2,000→2,500million
+25.0%
Ordinary income4,000→4,400million
+10.0%
Profit attributable to owners of the parent13,300→10,000million
-24.8%
Net income per share—→246.18Yen/sen
—

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

The outlook for Tabneos was reduced by ¥1,500 million, while sales were increased by ¥1,800 million mainly on expectations of higher orders in the information services business. Lower depreciation and amortisation expenses associated with the recognition of an extraordinary loss on long-term prepaid expenses, a review of expense allocations, and an increase in gross profit from higher sales in the information services business are expected, while net income attributable to owners of the parent was reduced by ¥3,300 million due to the impact of the recognition of extraordinary losses.

Details and amount of extraordinary loss

Impairment loss: ¥2,162 million; inventory valuation loss: ¥2,125 million (total extraordinary losses: ¥4,313 million)

Previous-period resultsNet sales: ¥97,406 million; operating loss: ¥2,927 million; ordinary loss: ¥1,162 million; net income attributable to owners of the parent: ¥13,779 million
Dividend forecast revisionNo revision
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net Sales¥88,700 million → ¥89,000 million
Operating profit¥2,000 million → ¥2,500 million
Ordinary income¥4,000 million → ¥4,400 million
Profit attributable to owners of the parent¥13,300 million → ¥10,000 million
Net income per shareNot disclosed → 246.18 Yen/sen
Fiscal Period CoveredFiscal year ending March 2027
Period CoveredFull year
Publication date of previous forecastJuly 2026
Previous-period resultsNet sales: ¥97,406 million; operating loss: ¥2,927 million; ordinary loss: ¥1,162 million; net income attributable to owners of the parent: ¥13,779 million
Reason for the revisionThe outlook for Tabneos was reduced by ¥1,500 million, while sales were increased by ¥1,800 million mainly on expectations of higher orders in the information services business. Lower depreciation and amortisation expenses associated with the recognition of an extraordinary loss on long-term prepaid expenses, a review of expense allocations, and an increase in gross profit from higher sales in the information services business are expected, while net income attributable to owners of the parent was reduced by ¥3,300 million due to the impact of the recognition of extraordinary losses.
Details and amount of extraordinary lossImpairment loss: ¥2,162 million; inventory valuation loss: ¥2,125 million (total extraordinary losses: ¥4,313 million)
Dividend forecast revisionNo revision
Consolidated / non-consolidatedConsolidated

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Net sales were reduced by ¥1,500 million following a further review of the outlook for the Tabneos product/service, but were increased by ¥1,800 million mainly on expectations of higher orders in the information services business. Operating profit and ordinary profit were revised upward based on expectations of lower depreciation and amortisation expenses associated with the recognition of an extraordinary loss on long-term prepaid expenses related to Tabneos, a review of expense allocations, and an increase in gross profit from higher sales in the information services business. Net income was revised downward due to the recognition of extraordinary losses, including an impairment loss and an inventory valuation loss related to Tabneos.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated) | KISSEI PHARMACEUTICAL CO.,LTD. (4547) timely disclosure | Komori